Medical News / Coverage ASRS 2019: Short-Term Effects of Ranibizumab Biosimilar Compared to Ranibizumab for DME

With fixed incomes a reality for many elderly patients, finding less expensive alternatives to current therapies is a hot topic for many retina specialists. Despite only being approved in India, the ranibizumab-biosimilar (Razumab) has caught the attention of many at the 2019 American Society of Retina Specialists Annual Meeting seeking an alternative treatment for patients with diabetic macular edema (DME). Source: MDmag By reading more or clicking on the link below, you are leaving this site and going to another site run by another organization

read more

Developing a greater understanding of associations and risk factors, even among common conditions, can pay great ... read more
A new era in the treatment of age-related macular degeneration could be on the horizon, as ... read more
Mixed in with the massive screens and eye-catching displays of the various companies use to represent ... read more
A new study examining the impact of guideline changes in Europe is suggesting use of topical ... read more